Who Paid My Doc
A Phase 3, 24-Week, Randomized, Double-Blind, Parallel-Group Bayesian
Research payments
$912,477
Through program year 2025, $912,477 in research payments was reported against A Phase 3, 24-Week, Randomized, Double-Blind, Parallel-Group Bayesian, across 182 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $169,131 | 50 |
| 2024 | Research | $431,909 | 93 |
| 2023 | Research | $311,438 | 39 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Lawrence Sher Rolling Hills Estates, CA Named on 16 payments
- Mark Vandewalker Columbia, MO Named on 11 payments
- Martha Tarpay Oklahoma City, OK Named on 11 payments
- Ileana Rodicio Miami, FL Named on 9 payments
- Dale Mohar Kerrville, TX Named on 8 payments
- Jaime Landman Fort Lauderdale, FL Named on 7 payments
- Jose Mandujano Frisco, TX Named on 5 payments
- Eric Boren Porterville, CA Named on 5 payments
- Lawrence Sindel Mobile, AL Named on 5 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.